Pre-Clinical Studies of Inactivated Polivalent Vaccine Against Hemorrhagic Fever with Renal Syndrome

Relevance. Hemorrhagic fever with renal syndrome (HFRS) is a non-transmissible viral zoonosis widespread in Eurasia, and in Russia it occupies a leading position among zoonotic viral infections and one of the first places among all natural focal human diseases. Aim. Obtaining evidence of the safety, quality and efficacy of a polyvalent vaccine against HFRS as a result of its preclinical studies using scientific assessment methods that meet the requirements and rules of good laboratory practice. Materials and methods. For preclinical studies of the polyvalent vaccine against HFRS, the materials and methods were used in strict accordance with the requirements of the regulatory documents, as well as previously described methods used to control the vaccine at the technological stages of its manufacture. Results. The data obtained as a result of preclinical studies of the polyvalent vaccine agains HFRS indicate a high immunogenicity and stability of the vaccine, the absence of: acute and chronic toxicity, allergenic, immunotoxic and mutagenic, as well as toxic effects on the reproductive organs of animals, embryo development and offspring, born to females who received the vaccine within 20 days of gestation. Conclusion. The obtained results of preclinical studies comply with the requirements for immunobiological medical preparations designed for humans, and are the basis for conducting the 1st phase of clinical trials the polyvalent vaccine against HFRS.

1. Federal Law of 12.04.2010 No. 61-ФЗ “On Circulation of Medicines”; 2010. (In Russ.)

2. «Rules of good laboratory practice». Order of the Ministry of Health of the Russian Federation of April 1, 2016 No. 1999N (Registered in the Ministry of Justice of the Russian Federation on August 15, 2016, registration No. 43232); 2016. (In Russ.)

3. «Guidelines for the study of the general toxic effect of drugs» in the book «Guidelines for the conduct of preclinical studies of drugs.Edited b y A. Mironov. Part One. M .: Grief and Co.; 2012. P. 13–51). (In Russ.)

4. «Guidelines for the evaluation of allergenic properties of drugs» (ib. P. 51–64). (In Russ.)

5. «Guidelines for the evaluation of the immunotoxic effect of drugs« (ib. P. 64–80). (In Russ.)

6. «Guidelines for the evaluation of mutagenic properties of drugs» (ib. P. 94–115). (In Russ.)

7. «Guidelines for the study of the immunotropic activity of drugs» (ib. P. 624–640). (In Russ.)

8. Guidelines for conducting preclinical studies of drugs. Ed. AN Mironova (Immunobiological drugs). Part two. M .: Grief and K; 2012. 536 p. (In Russ.)

9. Preclinical testing of new medical immunobiological preparations. The main provisions. RD 42-28-8-89. Moscow; 1989. (In Russ.)

10. Methodical recommendations of the Office of State Control medicines and medical equipment of the Ministry of Health of the Russian Federation of December 29, 1997. (In Russ.)

11. The European Convention for the Protection of Vertebrate Animals used for experimental and other scientific purposes of March 18, 1986. (Text modified in accordance with the provisions of the Protocol (ETS No. 170), its effective date is December 2, 2005). (In Russ.)

12. Annex 1, WHO guidelines on nonclinical evaluation of vaccines, WHO Technical Report Series, No. 927; 2005.

13. Barkhaleva OA, Vorobyova MS, Ladyzhenskaya IP, et al. Hemorrhagic fever vaccine with renal syndrome. Biological products. 2011;1:27–30. (In Russ.)

14. Dzagurova TK, Tkachenko EA, Yunicheva YuV, et al. Detection and clinical and etiological characteristics of HFRS in the subtropical zone of the Krasnodar Territory. ZhMEI. 2008;1:12–16. (In Russ.)